Clinical trials
Lupus Erythematosus, Systemic trials in Czechia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 2 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Terminated | 9 |
| Active, not recruiting | 8 |
| Recruiting | 4 |
| Enrolling by invitation | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 7 |
| UCB Pharma | 4 |
| EMD Serono | 3 |
| Eli Lilly and Company | 3 |
| Human Genome Sciences Inc., a GSK Company | 3 |
| Viatris Innovation GmbH | 3 |
| Biogen | 2 |
| Cephalon, Inc. | 2 |
| GlaxoSmithKline | 2 |
| ImmuPharma | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lupus Erythematosus, Systemic | 48 |
| Autoimmune Diseases | 10 |
| Lupus Nephritis | 7 |
| Connective Tissue Diseases | 6 |
| Immune System Diseases | 4 |
| Nephritis | 3 |
| Arthritis, Rheumatoid | 2 |
| Arthritis, Juvenile | 1 |
| Dermatomyositis | 1 |
| Glomerulonephritis | 1 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.